Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0275
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis ; volume:17 ; number:1 ; day:18 ; month:9 ; year:2020 ; pages:1-21 ; date:12.2020
Clinical proteomics ; 17, Heft 1 (18.9.2020), 1-21, 12.2020
- Creator
-
Guldbrandsen, Astrid
Lereim, Ragnhild Reehorst
Jacobsen, Mari
Garberg, Hilde
Kroksveen, Ann Cathrine
Barsnes, Harald
Berven, Frode S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12014-020-09296-5
- URN
-
urn:nbn:de:101:1-2020110719392437240810
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Guldbrandsen, Astrid
- Lereim, Ragnhild Reehorst
- Jacobsen, Mari
- Garberg, Hilde
- Kroksveen, Ann Cathrine
- Barsnes, Harald
- Berven, Frode S.
- SpringerLink (Online service)
Other Objects (12)
Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes
Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Cerebrospinal fluid analysis in multiple sclerosis
Towards optimised extracellular vesicle proteomics from cerebrospinal fluid
Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
Targeted proteomics on its way to discovery
Cerebrospinal fluid cells immune landscape in multiple sclerosis
Temporal proteomics of human cerebrospinal fluid after severe traumatic brain injury
Primary progressive multiple sclerosis (PPMS) – cerebrospinal fluid (CSF) profile
The clinical potential of blood-proteomics in multiple sclerosis
Profiling metabolic changes in breast cancer with targeted proteomics
Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes
Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Cerebrospinal fluid analysis in multiple sclerosis
Towards optimised extracellular vesicle proteomics from cerebrospinal fluid
Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
Targeted proteomics on its way to discovery
Cerebrospinal fluid cells immune landscape in multiple sclerosis
Temporal proteomics of human cerebrospinal fluid after severe traumatic brain injury
Primary progressive multiple sclerosis (PPMS) – cerebrospinal fluid (CSF) profile
The clinical potential of blood-proteomics in multiple sclerosis
Profiling metabolic changes in breast cancer with targeted proteomics
Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes
Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
Cerebrospinal fluid analysis in multiple sclerosis
Towards optimised extracellular vesicle proteomics from cerebrospinal fluid
Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
Targeted proteomics on its way to discovery
Cerebrospinal fluid cells immune landscape in multiple sclerosis
Temporal proteomics of human cerebrospinal fluid after severe traumatic brain injury
Primary progressive multiple sclerosis (PPMS) – cerebrospinal fluid (CSF) profile
The clinical potential of blood-proteomics in multiple sclerosis